Our author from today's excerpt is Dr. Stephen C. Taylor, Vice President, Fujifilm Diosynth Biotechnologies About 10 years ago as a vice president of Avecia Biologics, I wrote an article for an early issue of BioProcess International looking ahead at likely changes in biomanufacturing (1,2,3). For the best part of the intervening period, Avecia Biologics and Diosynth slugged it out in the marketplace, each trying to grow its contract manufacturing business at the expense of the other. But in a life-altering two-year period between 2009 and 2011, both companies saw their realities and perspectives change:
• Merck/MSD acquired Avecia Biologics.
• Merck/MSD and Schering Plough merged, bringing Avecia Biologics and Diosynth under the same corporate ownership.
• Fujifilm acquired the two CMO businesses from Merck/MSD, brought them together, and challenged them to operate as a single truly global contract manufacturing organization (CMO).
Thus in April 2011 Fujifilm Diosynth Biotechnologies was born, with the Diosynth name retained to reinforce Fujifilm's long-term commitment to the CMO business. It has been an interesting experience to bring two similar competitors together and get them to operate as one effective business. Faced with the question of how to bring this about, we decided to seek some common denominators. Both businesses had already adopted the “lean six sigma” (LSS) concept as a catalyst for driving business change and improvement, so we had our first point of overlap.
You can view the full article here. BPI will be joining us February 10-12 for IBC's 2nd Annual Flexible Facilities conference taking place this February. To learn more, view our agenda. Register with code FLEX14BLOG and save 20% off of the standard rate.We hope to see you February 24-25 in Berkley, CA!
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment